Challenges in the Infected Diabetic Foot: Osteomyelitis and Methicillin-Resistant Staphylococcus Aureus

The Foot in Diabetes: Fourth Edition

Volumn , Issue , 2006, Pages 169-185

  Berendt, Anthony R ^a   Lipsky, Benjamin A ^b,c  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF WASHINGTON   (United States)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

Bone destruction and infected diabetic foot; Diabetic foot osteomyelitis; Infected diabetic foot challenges; Isotope bone scans; Methicillin resistant S. aureus (MRSA); Osteomyelitis and pre existing neuropathic ulceration; Osteomyelitis prolonged antibiotic therapy; Penicillin resistance problem; Treating chronic osteomyelitis; Vancomycin resistance and community acquired MRSA

Indexed keywords

EID: 34548816287     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470029374.ch14     Document Type: Chapter

References (108)

1. Lipsky BA. Osteomyelitis of the foot in diabetic patients. Clin Infect Dis 1997;25:1318-1326.
2. Berendt AR, Lipsky BA. Bone and joint infections in the diabetic foot. Curr Treat Options Infect Dis 2003;5:345-360.
3. Mandal S, Berendt AR, Peacock SJ. Staphylococcus aureus bone and joint infection. J Infect 2002;44:143-151.
4. Ciampolini J, Harding KG. Pathophysiology of chronic bacterial osteomyelitis. Why do antibiotics fail so often?Postgrad Med J. 2000;76:479-483.
5. Lew DP, Waldvogel FA. Osteomyelitis. Lancet 2004;364:369-379.
6. Ellington JK, Harris M, Webb L, et al. Intracellular Staphylococcus aureus. A mechanism for the indolence of osteomyelitis. J Bone Joint Surg Br 2003;85:918-921.
7. Berendt AR, Lipsky B. Is this bone infected or not?Differentiating neuro-osteoarthropathy from osteomyelitis in the diabetic foot. Curr Diabetes Rep. 2004;4:424-429.
8. Snyder RJ, Cohen MM, Sun C, Livingston J. Osteomyelitis in the diabetic patient: diagnosis and treatment, Part 1: Overview, diagnosis, and microbiology. Ostomy Wound Manage 2001;47:18-22, 25-30; quiz 31-32.
9. Bonham P. A critical review of the literature, part I: diagnosing osteomyelitis in patients with diabetes and foot ulcers. J Wound Ostomy Continence Nurs 2001;28:73-88.
10. Wrobel JS, Connolly JE. Making the diagnosis of osteomyelitis. The role of prevalence. J Am Podiatr Med Assoc 1998;88:337-343.
11. Lipsky BA, Berendt AR, Deery HG, II, et al. IDSA Guidelines: Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004;39:885-910.
12. Newman LG,Waller J, Palestro CJ, et al. Unsuspected osteomyelitis in diabetic foot ulcers. Diagnosis and monitoring by leukocyte scanning with indium in 111 oxyquinoline. JAMA 1991;266:1246-1251.
13. Hill SL, Holtzman GI, Buse R. The effects of peripheral vascular disease with osteomyelitis in the diabetic foot. Am J Surg 1999;177:282-286.
14. Grayson ML, Gibbons GW, Balogh K, Levin E, Karchmer AW. Probing to bone in infected pedal ulcers: a clinical sign of underlying osteomyelitis in diabetic patients. JAMA 1995;273:721-723.
15. Armstrong DG, Lavery LA, Sariaya M, Ashry H. Leukocytosis is a poor indicator of acute osteomyelitis of the foot in diabetes mellitus. J Foot Ankle Surg 1996;35:280-283.
16. Kaleta JL, Fleischli JW, Reilly CH. The diagnosis of osteomyelitis in diabetes using erythrocyte sedimentation rate: a pilot study. J Am Podiatr Med Assoc 2001;91:445-450.
17. Upchurch GR Jr, Keagy BA, Johnson G Jr. An acute phase reaction in diabetic patients with foot ulcers. Cardiovasc Surg 1997;5:32-36.
18. Crim JR, Seeger LL. Imaging evaluation of osteomyelitis. Crit Rev Diagn Imaging 1994;35:201-256.
19. Becker W. Imaging osteomyelitis and the diabetic foot. Q J Nucl Med 1999;43:9-20.
20. ShultsDW, Hunter GC, McIntyre KE, Parent FN, Piotrowski JJ, Bernhard VM.Value of radiographs and bone scans in determining the need for therapy in diabetic patients with foot ulcers. Am J Surg 1989;158:525-529, discussion 529-530.
21. Dutronc H, Bocquentin F, Dupon M. [Radiographic diagnosis in bone and joint infection management]. Med Mal Infect 2004;34:257-263.
22. Blume PA, Dey HM, Daley LJ, Arrighi JA, Soufer R, Gorecki GA. Diagnosis of pedal osteomyelitis with Tc-99m HMPAO labeled leukocytes. J Foot Ankle Surg 1997;36:120-126, discussion 160.
23. Palestro CJ, Caprioli R, Love C, et al. Rapid diagnosis of pedal osteomyelitis in diabetics with a technetium-99m-labeled monoclonal antigranulocyte antibody. J Foot Ankle Surg 2003;42: 2-8.
24. Sarikaya A, Aygit AC, Pekindil G. Utility of 99mTc dextran scintigraphy in diabetic patients with suspected osteomyelitis of the foot. Ann Nucl Med 2003;17:669-676.
25. Poirier JY, Garin E, Derrien C, et al. Diagnosis of osteomyelitis in the diabetic foot with a 99mTc-HMPAO leucocyte scintigraphy combined with a 99mTc-MDP bone scintigraphy. Diabetes Metab 2002;28:485-490.
26. Harwood SJ, Valdivia S, Hung G-L, Quenzer RW. Use of sulesomab, a radiolabeled antibody fragment, to detect osteomyelitis in diabetic patients with foot ulcers by leukocintigraphy. Clin Infect Dis 1999;28:1200-1205.
27. Devillers A, Garin E, Polard JL, et al. Comparison of Tc-99m-labelled antileukocyte fragment Fab' and Tc-99m-HMPAO leukocyte scintigraphy in the diagnosis of bone and joint infections: a prospective study. Nucl Med Commun 2000;21:747-753.
28. Keidar Z, Militianu D, Melamed E, Bar-Shalom R, Israel O. The diabetic foot: initial experience with 18F-FDG PET/CT. J Nucl Med 2005;46:444-449.
29. Rubello D, Casara D, Maran A, Avogaro A, Tiengo A, Muzzio PC. Role of anti-granulocyte Fab' fragment antibody scintigraphy (LeukoScan) in evaluating bone infection: acquisition protocol, interpretation criteria and clinical results. Nucl Med Commun 2004;25:39-47.
30. Schweitzer ME, Morrison WB. MRimaging of the diabetic foot. Radiol Clin NorthAm2004;42:61-71, vi.
31. Chatha DS, Cunningham PM, Schweitzer ME. MR imaging of the diabetic foot: diagnostic challenges. Radiol Clin North Am 2005;43:747-759, ix.
32. Gil HC, Morrison WB. MR imaging of diabetic foot infection. Semin Musculoskelet Radiol 2004;8:189-198.
33. Dogan BE, Sahin G,Yagmurlu B, Erden I. Neuroarthropathy of the extremities: magnetic resonance imaging features. Curr Probl Diagn Radiol 2003;32:227-232.
34. Khatri G, Wagner DK, Sohnle PG. Effect of bone biopsy in guiding antimicrobial therapy for osteomyelitis complicating open wounds. Am J Med Sci 2001;321:367-371.
35. Zuluaga AF, GalvisW, Jaimes F, Vesga O. Lack of microbiological concordance between bone and non-bone specimens in chronic osteomyelitis: an observational study. BMC Infect Dis 2002;2:8.
36. Lipsky BA, Berendt AR. Principles and practice of antibiotic therapy of diabetic foot infections. Diabetes Metab Res Rev 2000;16:S42-S46.
37. Mader JT, Ortiz M, Calhoun JH. Update on the diagnosis and management of osteomyelitis. Clin Podiatr Med Surg 1996;13:701-724.
38. Bonham P. Acritical review of the literature, Part II: antibiotic treatment of osteomyelitis in patients with diabetes and foot ulcers. J Wound Ostomy Continence Nurs 2001;28:141-149.
39. Senneville E. Antimicrobial interventions for the management of diabetic foot infections. Expert Opin Pharmacother 2005;6:263-273.
40. Snyder RJ, Cohen MM, Sun C, Livingston J. Osteomyelitis in the diabetic patient: diagnosis and treatment, Part 2: Medical, surgical, and alternative treatments. Ostomy Wound Manage 2001;47:24-30, 32-41; quiz 42-43.
41. Van Damme H, Rorive M, Martens De Noorthout BM, Quaniers J, Scheen A, Limet R. Amputations in diabetic patients: a plea for footsparing surgery. Acta Chir Belg 2001;101:123-129.
42. Chang BB, Darling RC, III, Paty PS, Lloyd WE, Shah DM, Leather RP. Expeditious management of ischemic invasive foot infections. Cardiovasc Surg 1996;4:792-795.
43. Akbari CM, Pomposelli FB, Jr, Gibbons GW, et al. Lower extremity revascularization in diabetes: late observations. Arch Surg 2000;135:452-456.
44. Holstein PE, Sorensen S. Limb salvage experience in a multidisciplinary diabetic foot unit. Diabetes Care 1999;22:B97-B103.
45. Rauwerda JA. Surgical treatment of the infected diabetic foot. Diabetes Metab Res Rev 2004;20:S41-S44.
46. Pittet D, Wyssa B, Herter-Clavel C, Kursteiner K, Vaucher J, Lew PD. Outcome of diabetic foot infections treated conservatively: a retrospective cohort study with long-term follow-up. Arch Intern Med 1999;159:851-856.
47. Venkatesan P, Lawn S, Macfarlane RM, Fletcher EM, Finch RG, Jeffcoate WJ. Conservative management of osteomyelitis in the feet of diabetic patients. Diabet Med 1997;14:487-490.
48. Piaggesi A, Schipani E, Campi F, et al. Conservative surgical approach versus non-surgical management for diabetic neuropathic foot ulcers: a randomized trial. Diabet Med 1998;15:412-417.
49. Jeffcoate WJ, Lipsky BA. Controversies in diagnosing and managing osteomyelitis of the foot in diabetes. Clin Infect Dis 2004;39:S115-S122.
50. Ha Van G, Siney H, Danan JP, Sachon C, Grimaldi A. Treatment of osteomyelitis in the diabetic foot. Contribution of conservative surgery. Diabetes Care 1996;19:1257-1260.
51. Tan JS, File TM Jr. Diagnosis and treatment of diabetic foot infections. Baillieres Best Pract Res Clin Rheumatol 1999;13:149-161.
52. Henke PK, Blackburn SA,Wainess RW, et al. Osteomyelitis of the foot and toe in adults is a surgical disease: conservative management worsens lower extremity salvage. Ann Surg 2005;241:885-892, discussion 892-894.
53. Salvana J, Rodner C, Browner BD, Livingston K, Schreiber J, Pesanti E. Chronic osteomyelitis: results obtained by an integrated team approach to management. Conn Med 2005;69:195-202.
54. Rao N, Ziran BH, Hall RA, Santa ER. Successful treatment of chronic bone and joint infections with oral linezolid. Clin Orthop Relat Res 2004;427:67-71.
55. Lew DP, Waldvogel FA. Quinolones and osteomyelitis: state-of-the-art. Drugs 1995;49:100-111.
56. Tice A, Hoaglund P, Shoultz DA. Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy. Am J Med 2003;114:723-728.
57. Lazzarini L, Lipsky BA, Mader JT. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials?Int J Infect Dis. 2005;9:127-138.
58. Berendt AR, Lipsky BA. Should antibiotics be used in the treatment of the diabetic foot?Diabetic Foot. 2003;6:18-28.
59. Yamashita Y, Uchida A, Yamakawa T, Shinto Y, Araki N, Kato K. Treatment of chronic osteomyelitis using calcium hydraxyapatite ceramic implants impregnated with antibiotic. Int Orthop 1998;22:247-251.
60. Roeder B, Van Gils CC, Maling S. Antibiotic beads in the treatment of diabetic pedal osteomyelitis. J Foot Ankle Surg 2000;39:124-130.
61. Becker PL, Smith RA, Williams RS, Dutkowsky JP. Comparison of antibiotic release from polymethylmethacrylate beads and sponge collagen. J Orthop Res 1994;12:737-741.
62. Armstrong DG, Lipsky BA. Advances in the treatment of diabetic foot infections. Diabetes Technol Ther 2004;6:167-177.
63. Perencevich EN, Kaye KS, Strausbaugh LJ, Fisman DN, Harris AD. Acceptable rates of treatment failure in osteomyelitis involving the diabetic foot: a survey of infectious diseases consultants. Clin Infect Dis 2004;38:476-482.
64. Lipsky BA, Pecoraro RE, Wheat LJ. The diabetic foot. Soft tissue and bone infection. Infect Dis Clin North Am 1990;4:409-432.
65. Abbas ZG, Gill GV, Archibald LK. The epidemiology of diabetic limb sepsis: an African perspective. Diabet Med 2002;19:895-899.
66. Viswanathan V, Jasmine JJ, Snehalatha C, Ramachandran A. Prevalence of pathogens in diabetic foot infection in South Indian type 2 diabetic patients. J Assoc Physicians India 2002;50:1013-1016.
67. Cunha BA. Methicillin-resistant Staphylococcus aureus: clinical manifestations and antimicrobial therapy. Clin Microbiol Infect 2005;11:33-42.
68. Eady EA, Cove JH. Staphylococcal resistance revisited: community-acquired methicillin resistant Staphylococcus aureus-an emerging problem for the management of skin and soft tissue infections. Curr Opin Infect Dis 2003;16:103-124.
69. Favero MS. Outbreaks of community-associated methicillin-resistant Staphylococcus aureus skin infections. Infect Control Hosp Epidemiol 2003;24:787.
70. Tenover FC, McDonald LC. Vancomycin-resistant staphylococci and enterococci: epidemiology and control. Curr Opin Infect Dis 2005;18:300-305.
71. Sieradzki K, Markiewicz Z. Mechanism of vancomycin resistance in methicillin resistant Staphylococcus aureus. Pol J Microbiol 2004;53:207-214.
72. Cartolano GL, Cheron M, Benabid D, LeneveuM, BoisivonA. Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals. Clin Microbiol Infect 2004;10:448-451.
73. Apfalter P. [MRSA/MRSE-VISA/GISA/VRSA-PRP-VRE: current gram positive problem bacteria and mechanism of resistance, prevalence and clinical consequences]. Wien Med Wochenschr 2003;153:144-147.
74. Chang S, Sievert DM, Hageman JC, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003;348:1342-1347.
75. Vancomycin-resistant Staphylococcus aureus-Pennsylvania, 2002. MMWR Morb Mortal Wkly Rep 2002;51:902.
76. Methicillin-resistant Staphylococcus aureus skin or soft tissue infections in a state prison-Mississippi, 2000. MMWR Morb Mortal Wkly Rep 2001;50:919-922.
77. Methicillin-resistant Staphylococcus aureus infections in correctional facilities-Georgia, California, and Texas, 2001-2003. MMWR Morb Mortal Wkly Rep 2003;52:992-996.
78. Methicillin-resistant staphylococcus aureus infections among competitive sports participants-Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000-2003. MMWR Morb Mortal Wkly Rep 2003;52:793-795.
79. Centers for Disease Control and Prevention. Public health dispatch: outbreaks of communityassociated methicillin-resistant Staphylococcus aureus skin infections-Los Angeles County, California, 2002-2003. JAMA 2003;289:1377.
80. Community-associated methicillin-resistant Staphylococcus aureus infections in Pacific Islanders-Hawaii, 2001-2003. MMWR Morb Mortal Wkly Rep 2004;53:767-770.
81. Barrett TW, Moran GJ. Update on emerging infections: news from the Centers for Disease Control and Prevention. Methicillin-resistant Staphylococcus aureus infections among competitive sports participants-Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000-2003. Ann Emerg Med 2004;43:43-45, discussion 45-47.
82. Kazakova SV, Hageman JC, Matava M, et al.Aclone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med 2005;352:468-475.
83. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005;352:1436-1444.
84. Baggett HC, Hennessy TW, Rudolph K, et al. Community-onset methicillin-resistant Staphylococcus aureus associated with antibiotic use and the cytotoxin Panton-Valentine leukocidin during a furunculosis outbreak in rural Alaska. J Infect Dis 2004;189:1565-1573.
85. Tentolouris N, Jude EB, Smirnof I, Knowles EA, Boulton AJ. Methicillin-resistant Staphylococcus aureus: an increasing problem in a diabetic foot clinic. Diabet Med 1999;16:767-771.
86. Dang C, Prasad Y, Bouton A, Jude EB. Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabet Med 2003;20:159-61.
87. Fejfarova V, Jirkovska A, Skibova J, Petkov V. [Pathogen resistance and other risk factors in the frequency of lower limb amputations in patients with the diabetic foot syndrome]. Vnitr Lek 2002;48:302-306.
88. Grimble SA, Magee TR, Galland RB. Methicillin resistant Staphylococcus aureus in patients undergoing major amputation. Eur J Vasc Endovasc Surg 2001;22:215-218.
89. Mantey I, Hill RL, Foster AV, Wilson S, Wade JJ, Edmonds ME. Infection of foot ulcers with Staphylococcus aureus associated with increased mortality in diabetic patients. Commun Dis Public Health 2000;3:288-290.
90. Wagner A, Reike H, Angelkort B. [Highly resistant pathogens in patients with diabetic foot syndrome with special reference to methicillin-resistant Staphylococcus aureus infections]. Dtsch Med Wochenschr 2001;126:1353-1356.
91. Chopra I. Antibiotic resistance in Staphylococcus aureus: concerns, causes and cures. Expert Rev Anti Infect Ther 2003;1:45-55.
92. Marone P, Concia E, Andreoni M, Suter F, Cruciani M. Treatment of bone and soft tissue infections with teicoplanin. J Antimicrob Chemother 1990;25:435-439.
93. Paradisi F, Corti G, Messeri D. Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) antibiotics. Med Clin North Am 2001;85:1-17.
94. Raghavan M, Linden PK. Newer treatment options for skin and soft tissue infections. Drugs 2004;64:1621-1642.
95. Batts DH. Linezolid-a new option for treating gram-positive infections. Oncology (Williston Park) 2000;14:23-29.
96. Cepeda JA, Whitehouse T, Cooper B, et al. Linezolid versus teicoplanin in the treatment of Grampositive infections in the critically ill: a randomized, double-blind, multicentre study. J Antimicrob Chemother 2004;53:345-355.
97. Lipsky BA, Itani K, Norden C. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis 2004;38:17-24.
98. Weigelt J, Itani K, Stevens D, LauW, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005;49:2260-2266.
99. Rubinstein E, Keller N. Future prospects and therapeutic potential of streptogramins. Drugs 1996;51:38-42.
100. Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother 2005;55:240-245.
101. Lin G, Credito K, Ednie LM, Appelbaum PC. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob Agents Chemother 2005;49:770-772.
102. Mercier RC, Hrebickova L. Oritavancin: a new avenue for resistant Gram-positive bacteria. Expert Rev Anti Infect Ther 2005;3:325-332.
103. Stryjewski ME, O'Riordan WD, Lau WK, et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis 2005;40:1601-1607.
104. Bradford PA, Weaver-Sands DT, Petersen PJ. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 2005;41:S315-S332.
105. Appelbaum PC, Jacobs MR. Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria. Curr Opin Microbiol 2005.
106. Raboud J, Saskin R, Simor A, et al. Modeling transmission of methicillin-resistant Staphylococcus aureus among patients admitted to a hospital. Infect Control Hosp Epidemiol 2005;26:607-615.
107. Johnston P, Norrish AR, Brammar T, Walton N, Hegarty TA, Coleman NP. Reducing methicillinresistant Staphylococcus aureus (MRSA) patient exposure by infection control measures. Ann R Coll Surg Engl 2005;87:123-125.
108. Boyce JM, Havill NL, Kohan C, Dumigan DG, Ligi CE. Do infection control measures work for methicillin-resistant Staphylococcus aureus?Infect Control Hosp Epidemiol. 2004;25:395-401.